Ellin Berman MD

Ellin Berman is a board-certified medical oncologist and hematologist with a clinical and research focus on new drug development in acute and chronic leukemias, including acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). Her current research focuses on understanding how the cells within the bone marrow interact with leukemia cells. We have recently shown that the drug imatinib — one of a relatively new class of agents called tyrosine kinase inhibitors that inhibit growth of CML cells — can also inhibit other cells within the bone marrow that affect growth of bone. In conjunction with researchers here and at other institutions, we have begun to examine how cells within the bone marrow communicate with each other.